President Donald Trump said Wednesday his administration will propose banning thousands of flavors used in e-cigarettes to combat a recent surge in underage vaping.
CVS Health, which started carrying CBD skin products in some states this year, plans to remove Curaleaf products from its shelves following the FDA’s warning.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
The move comes as companies are turning to newer genetic engineering techniques that make it easier to tinker with the traits of plants and animals.
By clarifying terms such as “Sell by” and “Use by,” U.S. regulators are trying to prevent people from prematurely tossing products and to reduce the mountains of food that goes to waste each year.
Paul Elmer, who founded Pharmakon 16 years ago and shut it down three years ago, faces charges of adulterating compounded drugs, conspiracy and obstructing a U.S. FDA investigation.
Scott Gottlieb bucked expectations by pushing the agency to expand its authorities in several key ways, including an unprecedented effort to make cigarettes less addictive by requiring lower nicotine levels .
Congress legalized the production and sale of industrial hemp and hemp derivatives, including CBD. But FDA Commissioner Scott Gottlieb has restated his agency’s stance that CBD is a drug ingredient and therefore illegal to add to food or health products without his agency’s approval.
FDA Commissioner Scott Gottlieb said the FDA wanted to issue a warning about a new E. coli outbreak before people gathered for Thanksgiving meals, where the potential for exposure could increase.
The move represents a major step to further push down U.S. smoking rates, which have been falling for decades.
New limitations will be placed on e-cigarettes, according to a senior FDA official, restricting sales of many popular fruit flavors amid what the health agency has called an epidemic of youth use.
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.
President Donald Trump’s interest in the bill stems from a push by Vice President Mike Pence, who championed the initiative when he was governor of Indiana.
A notice posted on the Food & Drug Administration website says the eggs shipped to restaurants and grocery stores in nine states may be tainted with salmonella.
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
The Food and Drug Administration proposal will create new opportunities for drugmakers after repeated failures from companies including Indianapolis-based Eli Lilly and Co.